TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-08-08 am EDT
3765.00 JPY   +0.83%
08/04TAKEDA PHARMACEUTICAL : Quarterly Securities Report for the 1st Quarter
PU
08/03Poseida Therapeutics Shares Soar After Roche Collaboration
DJ
08/01Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical to Absorb Businesses From Unit Nihon Pharmaceutical

06/24/2022 | 08:26am EDT


© MT Newswires 2022
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
08/04TAKEDA PHARMACEUTICAL : Quarterly Securities Report for the 1st Quarter
PU
08/03Poseida Therapeutics Shares Soar After Roche Collaboration
DJ
08/01Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy
MT
07/29Takeda Pharmaceutical's Fiscal Q1 Attributable Profit Slides 24%
MT
07/28TRANSCRIPT : Takeda Pharmaceutical Company Limited, Q1 2023 Earnings Call, Jul 28, 2022
CI
07/28Takeda Posts Higher Fiscal Q1 Core Profit, Revenue
MT
07/28Takeda Pharmaceutical's First-Quarter Net Profit Fell 24% From High Base
DJ
07/28Takeda sees quarterly profit drop 39% after last year's one-time gains
RE
07/28Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Managem..
BU
07/28Takeda Pharmaceutical Company Limited Announces Dividend Guidance for Second Quarter an..
CI
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2023 3 756 B 27 741 M 27 741 M
Net income 2023 306 B 2 261 M 2 261 M
Net Debt 2023 3 038 B 22 439 M 22 439 M
P/E ratio 2023 18,9x
Yield 2023 4,82%
Capitalization 5 821 B 42 994 M 42 994 M
EV / Sales 2023 2,36x
EV / Sales 2024 2,28x
Nbr of Employees 47 347
Free-Float 96,8%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 734,00 JPY
Average target price 4 561,33 JPY
Spread / Average Target 22,2%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED19.03%42 640
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
PFIZER, INC.-16.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.1.95%244 068